You searched for "interview"
Zeiss field machines, public Wi-Fi risks and IoT scanning
End of support for old field machines Zeiss have recently announced that they are withdrawing support contracts for many of their older 7 series Humphrey Field Analysers (HFAs) in November 2017. They have confirmed maintenance contracts can continue, but repairs...Happy hour
Welcome Eye News Aug/Sep 2023, your bi-monthly tonic for a much-needed happy hour. In the current climate of challenge across all fronts, there’s no better time to reach out for the professional equivalent of a cheery cup in the company...100% Ophthalmology Programme Insights
We spoke to some of the Eye News family about their upcoming presentations at 100% Opthalmology, 24–26 February 2024, ExCeL London, UK.On reflection
Welcome one and all to our festive Eye News Dec/Jan 2024. The arrow of time has flown through 2023, landing us at the year’s end, but not before Santa brings you this special delivery. Aside from the partying and generally...
High dose (2.5mg) bevacizumab for postradiation cystoid macular oedema
The authors present a retrospective, interventional case series investigating the efficacy of high dose (2.5mg/0.1ml) intravitreal bevacizumab in the treatment of persistent postradiation (Iodine-125 plaque brachytherapy for uveal melanoma) cystoid macular oedema (CME). Persistent CME was defined as increased or...
Efficacy and safety of intravitreal aflibercept injection in wet age-related macular degeneration
This is a sub-group study of double masked review of patients randomised to different dosages and treatment frequency compared between aflibercept and ranibizumab treatment. This is to evaluate the efficacy and safety of intravitreal aflibercept (IVT-AFL) in Japanese patients with...Highlights from The RCOphth Annual Congress 2023
Check in here for live updates and media from the RCOphth Annual Congress 2023 being held in Birmingham's ICC between 22-25 May.
Post hoc analysis of the CANTREAT randomised trial
CANTREAT, a Canadian multicentre two-year randomised trial compares treat and extend treatment (T&E) relative to the monthly administration of Ranibizumab in nAMD. Two-hundred and eighty-five treatment-naïve patients with nAMD were randomised to receive either a once-monthly dosing or T&E regimen...Clinical trial investigates ‘Light Touch’ approach to wet AMD treatment
A clinical trial led by NIHR Moorfields Clinical Research Facility will explore a new ‘light-touch’ treatment approach for patients with neovascular age-related macular degeneration (wet AMD) that could result in fewer injections and reduced number of clinic visits. Funded by...The fragile p-value
Abdus Samad Ansari explores the limitation of the p-value and the application of the fragility index in clinical trials. Clinical trials and tribulations? The restoration of vision or more purely the gift of sight is an aspect of care that...What's trending Feb/Mar 2020
#gbhockey #samward #sight Great Britain Hockey player Sam Ward, described as one of the “deadliest attackers in world hockey” [1], sustained a sight-threatening injury after being struck in the face by a ball during the Olympic qualifying match against Malaysia...
